QuestionSBA
QuestionChoice
It is recommended to monitor parameters of growth (height and weight) for the duration of treatment with methylphenidate. It is not necessary to routinely check for a full blood count or to monitor renal function
34378
d
Full blood count, renal function and weight
QuestionChoice
It is recommended to monitor parameters of growth (height and weight) for the duration of treatment with methylphenidate. It is not necessary to routinely check for a full blood count or to monitor serum prolactin
34379
e
Height, full blood count and serum prolactin
QuestionChoice
It is recommended to perform an ECG before commencing methylphenidate and to monitor blood pressure for the duration of treatment. Monitoring serum prolactin is not necessary
34376
b
Blood pressure, ECG and serum prolactin
QuestionChoice
It is recommended to monitor blood pressure as well as parameters of growth (height and weight) for the duration of treatment with methylphenidate
34375
a
Blood pressure, height and weight
QuestionChoice
It is recommended to monitor blood pressure as well as parameters of growth (height and weight) for the duration of treatment with methylphenidate. It is not necessary to monitor renal function
34377
c
ECG, height and renal function
Concept
Chapter
#### Monitoring

The BNF advises to monitor lung function (in patients with a history of obstructive airway disease).

#### Overdoses

Overdosages with beta-blockers may cause cardiac effects such as bradycardia, hypotension, syncope, conduction abnormalities, and heart failure. Bradycardia is the most common arrhythmia, but some beta-blockers may induce ventricular tachyarrhythmias secondary to prolongation of QT interval (e.g. sotalol) or QRS duration (e.g. propranolol).
Non-cardiovascular effects include central nervous system effects (including drowsiness, confusion, convulsions, hallucinations, and in severe cases coma), respiratory depression, and bronchospasm.

Management
 - Airway protection 
 - Activated charcoal within 1 hour
 - IV Fluids
 
IV glucagon is the first-line management.
 
For symptomatic bradycardia, IV atropine may be used.

2618
2818
Methylphenidate monitoring
Topic
91
Paediatrics
6886
Case Presentation: A 9 year old boy attends a specialist paediatric review with his parents. He has previously been suspended from school for being disruptive and refusing to settle during class. At home, his mother struggles to make him focus on his homework and conform to bedtimes, sometimes finding him awake and playing loudly in his bedroom past midnight. A trial of a low-sugar diet has failed to ameliorate his behavioural symptoms.


Treatment with methylphenidate hydrochloride 5mg PO OD is to be commenced.

Question: Select the most appropriate option to monitor for adverse effects of this treatment.
a